NEW YORK, NY / ACCESSWIRE / August 1, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
IonQ, Inc. (NYSE:IONQ)
CONTACT JAKUBOWITZ ABOUT IONQ:
Class Period : March 30, 2021 - May 2, 2022
Lead Plaintiff Deadline : August 1, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) IonQ had not yet developed a 32-qubit quantum computer; (2) the Company's 11-qubit quantum computer suffered from significant error rates, rendering it useless; (3) IonQ's quantum the computer is not sufficiently reliable, so it is not accessible despite being available through major cloud providers; (4) a significant portion of IonQ's revenue was derived from improper roundtripping transactions with related parties; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were the materially misleading and/or lacked a reasonable basis.
Energy Transfer LP (NYSE:ET)
CONTACT JAKUBOWITZ ABOUT ET:
This lawsuit is on behalf of persons who purchased or otherwise acquired common shares of Energy Transfer stock between April 13, 2017 and December 20, 2021, both dates inclusive.
Lead Plaintiff Deadline : August 2, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) Energy Transfer had inadequate internal controls and procedures to prevent contractors from engaging in illegal conduct with regards to drilling activities, and/or failed to properly mitigate known issues related to such controls and procedures; (b) Energy Transfer, through its subsidiary Rover Pipeline, LLC, hired a third-party contractor to conduct Horizontal Directional Drilling Activities for the Rover Pipeline Project, whose conduct of adding illegal additives in the drilling mud caused severe pollution near the Tuscarawas River when a large inadvertent release took place on April 13, 2017; (c) Energy Transfer continually downplayed its potential civil liabilities when the Federal Energy Regulatory Commission ("FERC") was actively investigating the Energy Transfer's wrongdoing related to the April 13 release and consistently provided it with updated information about FERC's findings on this matter.
Molecular Partners AG (NASDAQ:MOLN)
CONTACT JAKUBOWITZ ABOUT MOLN:
This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021; and/or (b) Molecular Partners securities between June 16, 2021, and April 26, 2022.
Lead Plaintiff Deadline : September 12, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration ("FDA") was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization ("EUA"); (iii) waning global rates of COVID-19 significantly reduced the Company's chances of securing EUA for ensovibep; (iv) another of the Company's product candidates, MP0310, was less attractive to Molecular Partners' collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company's initial public offer and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE : Jakubowitz Law